Device Trial Radar · NCT07281599
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Dec 31, 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- QurasenseNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- Female only, from 25 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing. The same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.
Conditions
- HPV Infection
- HPV 16 Infection
- High Risk HPV
- Cervical Cancer Screening
- Cervical Cancer Cin Grade
- Cervical Cancer (Early Detection)
- HPV
- HPV (Human Papillomavirus)-Associated
- HPV DNA
- HPV Infections
- Screening Test
Interventions
Q-Pad hrHPV Test SystemDevice
Participants will receive a mailed Q-Pad Kit, which includes two Q-Pads (menstrual pads with removable collection strips called Q-Strips), a Q-Strip Container with desiccant for storing and shipping the strips, and a prepaid return mailer. During the menstrual cycle after their colposcopy visit, participants will follow the Instructions for Use to passively collect menstrual blood with the Q-Pads, then remove the Q-Strips and place them in the Q-Strip Container for mailing to the central laboratory for hrHPV testing. At the colposcopy visit, the clinician will also collect a cervical sample in ThinPrep liquid-based cytology medium for hrHPV testing, which will serve as the comparator specimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Performance vs HistologyTime frame: Through study completion, an average of 1 year.
- Proportion of participants with at least one reportable device-related adverse event (ADE or SADE)Time frame: Through study completion, an average of 1 year.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Planned Parenthood of Southern New England
New Haven, Connecticut · Recruiting
Planned Parenthood North Central States
Minneapolis, Minnesota · Recruiting
Planned Parenthood of Greater Ohio (PPGOH)
Akron, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.